id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
bptjm-22	Hrishikesh Bhagwat; Bronstein, Sophie; Bhatt, Anar; Nguyen, Vanloan	Neurogenesis: Gene-Based Strategies for Treating Ischemic Stroke	2022	27	.pdf	application/pdf	9830	684	60	While�stroke�continues�to�be�among�the�most�debilitating�illnesses,�current� treatments� for� stroke�are� limited�by� their�time�of�administration�and�most� notably� cannot� reverse� tissue� damage� once� it� has� occurred. � These� include� thrombolysis,� the� chemically� induced� breakdown� of� blood� clots,� and� thrombectomy,� the� surgical� removal�of� the�blood�clots�with�a�catheter4.�A� stroke� patient� must� receive� the� standard� thrombolytic� treatment,� tissue� plasminogen�activator�(tPA),�within�4�½�hours�of�onset,�and�patients�above� 80�years�of�age�must�receive�tPA�within�3�hours5.�Moreover,�tPA�comes�with� the�risk�of�hemorrhage,�neurologic�decline�and�orolingual�angioedema6,�and� its�positive�outcome� rate� is�estimated�to�be�only�43%5.�Thrombectomy�is�a� more�versatile�option�because�of�its�ability�to�treat�patients�with�a�proximal� occlusion,� unlike� thrombolysis.	cache/bptjm-22.pdf	txt/bptjm-22.txt